HY001N for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.
HY001N for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.
Recruiting · NCT07748533 · Registry updated 2026-08-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| HY001N for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy. | Hemic and Lymphatic Diseases, anemia, autoimmune disease, autoimmune hemolytic anemia, hematologic disorder, hemolytic anemia, immune system disorder | Recruiting | Phase 1 | 2026-08-05 | NCT07748533 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Juventas Cell Therapy Ltd. | 16 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Institute of Hematology & Blood Diseases Hospital | Tianjin | China | 12 |